COMMUNIQUÉS West-GlobeNewswire

Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
12/08/2026
Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX [...]
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
12/08/2026
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing [...]
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12/08/2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases [...]
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12/08/2026
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 [...]
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA [...]
Persephone Biosciences Publishes Largest U.S. Clinical Study of an Infant Synbiotic in Pediatric Research, Expanding Clinical Evidence for Its Infant Synbiotics
12/08/2026
Publication reports results from the largest U.S. randomized trial evaluating a synergistic Bifidobacterium-HMO synbiotic in infants and toddlers, demonstrating safety, successful gut colonization and biologically [...]
Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
12/08/2026
NAPLES, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced [...]
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug [...]
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
12/08/2026
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled [...]
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
12/08/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Two candidates nominated for development in Acumen’s [...]
Kamada Announces Planned Transition of Chief Financial Officer
12/08/2026
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious [...]
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and [...]
BioPorto A/S to host an investor webcast on the results for the first half of 2026
12/08/2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO [...]
NovelMed Advances NM5072 for Multiple Ocular Disorders
11/08/2026
Key Highlights Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single [...]
Five Years of Unprecedented Growth: TimelyCare Redefines Student Well-Being
11/08/2026
Latest Inc. 5000 ranking cements TimelyCare’s position as a trusted, high-impact partner for educational communities. Fort Worth, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- TimelyCare, education’s most trusted virtual care [...]
Rampart Withdraws Appeal of USPTO’s Invalidation Decision
11/08/2026
ST. PAUL, Minn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Egg Medical announced today that Rampart IC, LLC (“Rampart”) withdrew its appeal of the USPTO’s reexamination decision that the claims of Rampart’s U.S. Patent No. 11, [...]
ASHA Names 2026 Media Champion Award Recipients
11/08/2026
Rockville, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The American Speech-Language-Hearing Association (ASHA) announced the recipients of ASHA’s 2026 Media Champion Awards today. These awards recognize media outlets, ASHA [...]
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08/2026
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway [...]
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
11/08/2026
Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 [...]

Pages